US Budget Stopgap, FDA User Fee Reauthorization On Tap Minus Supplement MPL Program
With current user fee package as well all federal spending programs for FY2022 expiring on 30 September, House and Senate committee leaders reach agreement on FDA user fee reauthorization included in a continuing resolution to extend federal spending at current levels through 16 December.
You may also be interested in...
AHPA urges chairs and ranking members of Senate HELP and House Energy and Commerce committees not to pass mandatory product listing legislation or make other changes to FDA regulation of industry before the 117th Congress ends. NPA board members lobby lawmakers about the topic.
Agency publishes Prescription Drug User Fee Act rates for FY2023, the first of five covered in reauthorization of program Congress approved on 30 September as legislation added to a continuing resolution to fund federal agencies through 16 December.
US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation
Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.